APA (7th ed.) Citation

Laubach, J. P., Liu, C., Raje, N. S., Yee, A. J., Armand, P., Schlossman, R. L., . . . Ghobrial, I. M. (2019). A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma. Clinical cancer research, 25(2), 478-486. https://doi.org/10.1158/1078-0432.CCR-18-1325

Chicago Style (17th ed.) Citation

Laubach, Jacob P., et al. "A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or Without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma." Clinical Cancer Research 25, no. 2 (2019): 478-486. https://doi.org/10.1158/1078-0432.CCR-18-1325.

MLA (9th ed.) Citation

Laubach, Jacob P., et al. "A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or Without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma." Clinical Cancer Research, vol. 25, no. 2, 2019, pp. 478-486, https://doi.org/10.1158/1078-0432.CCR-18-1325.